Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
CASI Pharmaceuticals, Inc (DE) (CASI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/21/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
01/31/2023 8-K Acquisition/merger/asset purchase announced
Docs: "THE MERGER"
11/14/2022 8-K Quarterly results
09/23/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products , today announced that CASI Biopharmaceuticals Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. , entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP , pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology Co., Ltd. amounting to 12.0098% total Juventas equity to Jiadao Gongcheng for RMB 240.87 million . The Equity Transfer Agreement states there will be two even payment installments from Jiadao Gongcheng: one payment to be made..."
08/12/2022 8-K Quarterly results
Docs: "CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2022. Wei-Wu He, Ph.D., CASI’ s Chairman and Chief Executive Officer, commented, “We are pleased to report $8.6 million in EVOMELA ® sales revenue for the second quarter of 2022. This is an increase of 19% compared to the same period last year. Our sales and marketing team is proven to be resilient, rapidly adapting strategies to address COVID-19 related challenges to ensure that our priories remain on track.” Dr. He continued, “Equipped with experience from EVOMELA and the ab..."
05/26/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA ® REVENUE"
03/04/2022 8-K Quarterly results
02/16/2022 8-K Quarterly results
Docs: "CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES"
01/03/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE ROCKVILLE, MD., and BEIJING CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that on December 30, 2021 CASI received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying CASI that, for the previous 30 consecutive business days, the bid price of CASI’ s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550 . The Nasdaq deficiency letter has no immediate effect on the listing of CASI’ s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Ru..."
12/17/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that its board of directors approved a stock repurchase program for the repurchase of up to USD 10 million of the Company’ s common stock through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934 and through trading plans established pursuant to Rule 10b5-1 of the Securities Exchange Act. Under any Rule 10b5-1 trading plan the Company might adopt, the Company’ s third-party broker, subject to Securities and Exchange Commission regulations regarding certain price, market, volume and tim..."
12/10/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS"
10/29/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "9620 Medical Center Drive, Suite 300"
08/12/2021 8-K Quarterly results
Docs: "CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS"
07/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/21/2021 8-K/A Quarterly results
06/16/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/30/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/26/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy